Sign in
CompletedPhase 4

PENG Block Optimization: Volume and Dexamethasone Effects

Key facts

Who runs it
Poznan University of Medical Sciences
Where
Poland1 site in 1 countryChoose a country to see its sites
Trial code
Status
Completed
Phase
Phase 4
People taking part
120 people enrolled
Started
25 Jun 2025
Ended
20 Feb 2026
Type of study
Interventional, 4 groupsOne group gets an existing treatment, for comparison.
Treatments tested
  • Ropivacaine 0.2% Injectable Solution
  • Dexamethasone 4mg
Record updated
16 March 2026

Who can take part

Age
60 years to 100 years
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 14 criteriaShow less

Who can take part

  • Adults aged ≥18 years scheduled for primary unilateral total hip arthroplasty (THA)
  • American Society of Anesthesiologists (ASA) physical status I-III
  • Ability to provide written informed consent
  • Spinal anesthesia planned as the primary anesthetic technique
  • Body mass index (BMI) between 18 and 35 kg/m²
  • Fluent in the local language and able to understand the NRS pain scoring system

Who cannot take part

  • Chronic opioid use (daily use >30 mg oral morphine equivalents for >1 month prior to surgery)
  • Previous surgery or implantation on the ipsilateral hip
  • Known allergy or hypersensitivity to ropivacaine, dexamethasone, or other amide local anesthetics
  • History of coagulopathy, current anticoagulant therapy not eligible for regional anesthesia
  • Uncontrolled diabetes mellitus (HbA1c > 9%) or active systemic infection
  • Pre-existing neurological deficits or neuropathies affecting lower limb motor or sensory function
  • Pregnancy or breastfeeding
  • Inability to cooperate with postoperative assessments or participate in follow-up

Where is this trial?

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

This randomized controlled trial investigates the impact of local anesthetic volume and perineural dexamethasone on the analgesic and anti-inflammatory effectiveness of the pericapsular nerve group (PENG) block in patients undergoing total hip arthroplasty (THA). Patients were randomized to receive one of four PENG block variants differing in ropivacaine volume (10 mL or 20 mL of 0.2%) and the addition of 4 mg of perineural dexamethasone. The study evaluates postoperative pain, opioid requirements, systemic inflammatory markers, and quadriceps motor preservation.

The 4 groups in the trial

  • PENG 20 mLExisting treatment, for comparison

    Ultrasound-guided PENG block - 20ml 0,2% ropivacaine

    Treatment: Ropivacaine 0.2% Injectable Solution

  • PENG 20 mL + DEXExisting treatment, for comparison

    Ultrasound-guided PENG block - 20ml 0,2% ropivacaine + 4mg Dexamethasone

    Treatment: Ropivacaine 0.2% Injectable Solution and Dexamethasone 4mg

  • PENG 10 mLExisting treatment, for comparison

    Ultrasound-guided PENG block - 10ml 0,2% ropivacaine

    Treatment: Ropivacaine 0.2% Injectable Solution

  • PENG 10 mL + DEXExisting treatment, for comparison

    Ultrasound-guided PENG block - 10ml 0,2% ropivacaine + 4mg Dexamethasone

    Treatment: Dexamethasone 4mg and Ropivacaine 0.2% Injectable Solution

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
Optimizing PENG Block in Hip Arthroplasty: Influence of Ropivacaine Volume and Dexamethasone on Analgesic Efficacy
Record updated
16 March 2026